UPPSALA, SE — November 11, 2025 — Leads & Copy — Senzime (STO:SEZI)(OTCQX:SNZZF) CEO Philip Siberg will present at two investor conferences this week, the company announced today.
Siberg will first present at the Redeye Medtech & Diagnostics Theme Event on November 12, 2025, at 11:45 CET. Interested parties can find more information on the event page at https://www.redeye.se/events/1110236/redeye-theme-medtech-diagnostics-4.
The CEO will then present at the Biostock Summit on November 13, 2025, at 14:40 CET. More information is available on the event page at https://biostock.se/event/biostock-life-science-summit/.
After the events, the presentations will be available on Senzime’s website.
Senzime, established in 1999 and headquartered in Uppsala, Sweden, develops and markets precision-based monitoring systems to improve outcomes, reduce costs, and advance patient safety. Its flagship solution is the TetraGraph® system, which provides accurate monitoring of neuromuscular transmission during surgery. Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI) and the US OTCQX Market (SNZZF).
Philip Siberg, CEO of Senzime AB, can be reached by phone at +46 (0) 707 90 67 34, or via email at philip.siberg@senzime.com.
Source: Senzime
